{"id":545448,"date":"2026-07-17T03:38:12","date_gmt":"2026-07-17T03:38:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/545448\/"},"modified":"2026-07-17T03:38:12","modified_gmt":"2026-07-17T03:38:12","slug":"repligen-rgen-stock-looks-fairly-valued-on-cash-flow-but-fully-priced-on-sales","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/545448\/","title":{"rendered":"Repligen (RGEN) Stock Looks Fairly Valued On Cash Flow But Fully Priced On Sales"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. <\/p>\n

Repligen stock is coming off a mixed five year stretch, with the share price lower over that window even as more recent returns have turned positive. The valuation signals now point to a stock that is not clearly cheap, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting close to the current market price while traditional multiples lean expensive. <\/p>\n

Repligen shares are down 27.9% over five years, which puts the current valuation debate in the context of a long period where holders have not been rewarded for staying invested. <\/p>\n

Expectations around Repligen’s ability to convert its opportunity set into reliable cash flows can support the current price, but any setback in execution or profitability may weigh heavily on what investors are willing to pay. <\/p>\n

Repligen scores 1 out of 6 on our broader valuation checks, which suggests the stock leans expensive rather than standing out as a clear bargain on these measures 1\/6<\/a>. <\/p>\n

The issue now is whether Repligen’s current share price around US$148.55 still offers a reasonable entry point, given a fairly valued intrinsic estimate and richer market multiples. <\/p>\n

Find out why Repligen’s 19.8% return over the last year is lagging behind its peers.<\/a> <\/p>\n

Is Repligen Fairly Priced on Cash Flow? <\/p>\n

The Discounted Cash Flow (DCF) model used here estimates what Repligen’s future cash generation could be worth in today’s dollars. Repligen has latest twelve month free cash flow of about $95.8 million, and the model assumes those cash flows continue growing from this base over time rather than shrinking. <\/p>\n

Based on these assumptions, the DCF model points to an intrinsic value of around $164.55 per share, compared with the current price near $148.55. That gap implies the stock trades at roughly a 9.7% discount to the cash flow estimate, which is meaningful but not extreme, particularly given how sensitive DCF outcomes are to growth and discount rate inputs. <\/p>\n

Overall, the DCF analysis indicates that Repligen stock appears roughly fairly valued, with only a modest difference between price and intrinsic value. <\/p>\n

Repligen is fairly valued according to our Discounted Cash Flow (DCF)<\/a>, but this can change at a moment’s notice. Track the value in your watchlist<\/a> or portfolio<\/a> and be alerted on when to act. <\/p>\n

\"RGEN<\/a> RGEN Discounted Cash Flow as at Jul 2026 <\/p>\n

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Repligen.<\/a> <\/p>\n

Is Repligen Getting Expensive on Sales? <\/p>\n

Story Continues <\/p>\n

The P\/S multiple can be useful for Repligen because revenue tends to be less affected by accounting choices than earnings, which can make it a cleaner way to compare valuation. Repligen currently trades at a P\/S of about 11.0x, which is well above the Life Sciences industry average of roughly 3.9x and also higher than the peer group average of about 3.9x. <\/p>\n

A tailored fair P\/S ratio for Repligen, which adjusts for the company’s growth profile, margins, size and risk, is estimated at about 5.6x. Compared with that benchmark, the current 11.0x level implies investors are paying roughly double what this framework would suggest for each dollar of sales. That indicates expectations already built into the price that leave less room for disappointment if Repligen’s revenue or profitability trends differ from what the market appears to be assuming. <\/p>\n

On this sales-based yardstick, Repligen stock appears overvalued, with the current P\/S multiple sitting well above both these fair value estimates and sector norms. <\/p>\n

\"NasdaqGS:RGEN<\/a> NasdaqGS:RGEN P\/S Ratio as at Jul 2026 <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

The Repligen Narrative: What Would Justify Today’s Price? <\/p>\n

Simply Wall St Narratives for Repligen extend the valuation work by setting out clear, data driven stories about what Repligen’s growth, margins and earnings would need to look like for the stock to be worth materially more or less than today’s price. These Narratives sit on the company’s Community page. Where a ratio or model gives a single figure, these Narratives describe the future it relies on so you can watch how reality lines up with that path over time. <\/p>\n

The community is split on Repligen, with one camp focused on recovery potential and the other fixated on how much could still go wrong. <\/p>\n

Bull case: 16% undervalued <\/p>\n

“Continued product launches (new resins, Metenova single-use mixers, integrated PAT platforms) and recent acquisitions (e.g., 908 bioprocessing) are building additional recurring consumable pull-through and expanding the addressable market, directly supporting long-term revenue and operating margin growth…” <\/p>\n

Read the full Bull Case<\/a> to see why Repligen could be undervalued<\/a> <\/p>\n

Bear case: roughly fairly valued <\/p>\n

“Exposure to macroeconomic instability, supply chain disruption, and customer concentration risks could dampen Repligen’s future revenue growth and margin expansion efforts…” <\/p>\n

Read the full Bear Case<\/a> to see why Repligen could be overvalued<\/a> <\/p>\n

Do you think there’s more to the story for Repligen? Head over to our Community to see what others are saying!<\/a> <\/p>\n

The Bottom Line <\/p>\n

For Repligen, the Discounted Cash Flow (DCF) intrinsic value estimate sits only modestly above the current share price, while sales based multiples point to the stock trading on the expensive side. That mix suggests Repligen is no longer an obvious bargain, especially given the weak read across broader valuation checks. The crux from here is whether the company can deliver the revenue growth and margins implied by its premium P\/S multiple, rather than just meeting the more forgiving cash flow path embedded in the DCF. How confidently you answer that question is likely to drive your stance on the stock. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include RGEN<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":545449,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,3297,78797,85,77209,46,208688,13132,39402],"class_list":["post-545448","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-cash-flow","tag-discounted-cash-flow","tag-il","tag-intrinsic-value","tag-israel","tag-repligen","tag-share-price","tag-stock-trades"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/545448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=545448"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/545448\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/545449"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=545448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=545448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=545448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}